Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025JAMA Oncology

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJeffrey A. MeyerhardtTTTyler S. TwomblyLPLevi Pederson

Discussion

Loading...

Member takes

Overview

Observational analysis shows ctDNA status predicts survival in stage III colon cancer patients receiving adjuvant celecoxib and chemotherapy, highlighting its possible prognostic value.

Key Points

  • To investigate the predictive value of postoperative ctDNA for survival outcomes with adjuvant celecoxib in stage III colon cancer.
  • Post hoc analysis of phase 3 trial assessing adjuvant celecoxib vs placebo
  • Patients had ctDNA analysis performed post-surgery prior to adjuvant therapy
  • Examined disease-free survival and overall survival by ctDNA status
  • Among 940 patients, 18.4% were ctDNA positive; influenced disease-free survival and overall survival
  • ctDNA positivity linked with worse disease-free survival and overall survival (aHR 6.12 and 5.86)
  • In ctDNA positive patients, celecoxib improved disease-free survival (aHR 0.61) and overall survival (aHR 0.62) compared to placebo.

Cite This Study

Meyerhardt et al. (2025) studied this question.

synapsesocial.com/papers/693624ce4fa91c937236cdb5https://doi.org/10.1001/jamaoncol.2025.5144
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Postoperative circulating tumor DNA for recurrence risk assessment and adjuvant therapy decision-making in resected colorectal cancer: A systematic review and meta-analysis.2026
  2. 2Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer2025
  3. 3Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay2025
  4. 4Prognostic Value of Circulating Tumor DNA in HR+/HER2− Stage I–III Breast Cancer: A Systematic Review2025
  5. 5Circulating tumour DNA-guided second-line targeted therapy for patients with metastatic colorectal cancer after failure of first-line cetuximab-based treatment: A prospective, phase II trial2025